Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

NCT03778931 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

478

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Elacestrant
DRUG: Standard of Care

Sponsor

Stemline Therapeutics, Inc.